MET and non-small cell lung carcinoma: In addition, savolitinib treatment exhibited substantial anti-tumor activity in vivo (tumor regression: 35%) in the NSCLC cancer cell line NCI-H820 harboring an activating EGFR mutation (Ex19del), a gefitinib/erlotinib resistant mutation (T790M) as well as hyperactivated MET (data on file).